|
Analytical technique used | Cancer type | Cell lines studied | Control | Type of matrix | Reference |
|
SPME-GC-MS | Lung cancer | A549 | OUS11 and WI-38 VA 13 | Cell-free culture medium | [79] |
|
SPME-GC-MS | Skin cancer | RPG: M35, WM3211, and Sbcl2 VPG: WM115 and WM983A Mm: WM983B and WM1158 | FOM136, FOM191, and pure medium | Cell-free culture medium | [70] |
|
SPME-GC-MS | Lung cancer | A549, SK-MEM-1, and NCIH 446 | BEAS2B | Cell-free culture medium | [76] |
|
SPME-GC-MS | Colon cancer | SW1116 and SW480 | NCM460, pure medium | Culture medium with cells | [69] |
|
SPME-GC-MS | Lung cancer | Primary lung cancer cells | Primary normal cells (human lung cells, lipocytes, osteogenic cells, and rat taste bud cells) | Cell-free culture medium | [78] |
|
SPME-GC-MS | Lung cancer | A549 | Pure medium | Culture medium with cells | [87] |
|
Nanosensors (quartz microbalances), SPME-GC-MS | Melanoma, synovial sarcoma, and thyroid cancer | Primary cells | Pure medium | Culture medium with cells | [154] |
|
Ultra II SKC-GC-MS, nanosensors (gold nanoparticles) | Lung cancer | NSCLC: A549, Calu-3, H1650, H4006, H1435, H820, and H1975 | Pure medium | Culture medium with cells | [123] |
|
Ultra II SKC-GC-MS, nanosensors (gold nanoparticles) | Lung cancer | NSCLC: A549, Calu-3, H1650, H4006, H1435, H820, H1975, H2009, HCC95, HCC15, H226, and NE18 SCLC: H774, H69, H187, and H526 | IBE, pure medium | Culture medium with cells | [73] |
|
ORBOTM 420 Tenax TA sorption tubes-GC-MS, nanosensors (gold nanoparticles; single walled carbon nanotubes) | Liver cancer | MHCC97-H, MHCC97-L, HepG2, SMMC-7721, and BEL-7402 | L-02 | Culture medium with cells | [71] |
|
PT-GC-MS | Lung cancer | Calu-1 | Pure medium | Culture medium with cells | [15] |
|
PT-GC-MS | Lung cancer | NCI-H2087 | Pure medium | Culture medium with cells | [72] |
|
PT-GC-MS | Lung cancer | A549 | HBEpC, hFB, and pure medium | Culture medium with cells | [80] |
|
DNTD-GC-MS | Liver cancer | HepG2 | Pure medium | Culture medium with cells | [122] |
|
pMC-GC-MS (p: cryogenic) | Leukaemia | HL60 | Pure medium | Culture medium with cells | [125] |
|
SIFT-MS | Breast cancer | MCF-7 and MCF-7Adr | ns | Cell lysate | [155] |
|
p-SIFT-MS (p: distillation) | Breast, leukaemia, cervical, and prostate cancer | MCF-7, MCF-7Adr, HeLa S3, K562, LNCaP, and DU-145 | Solid residue left after centrifugation | Cell lysate | [156] |
|
p-SIFT-MS | Breast cancer | MCF-7 and MCF-7Adr | Solid residue left after centrifugation | Cell lysate | [157] |
|
SIFT-MS | Lung cancer | CALU1 | NL20, pure medium | Medium with cells | [81] |
|
PTR-MS | Lung cancer | A549 and EPLC | hTERT-RPE1, BEAS2B, and pure medium | Medium with cells | [74] |
|
SIFT-MS | Lung cancer | Calu1 and SK-MEM-1 | Pure medium | Medium with cells | [82] |
|
SIFT-MS | Lung cancer | Calu-1 | NL20, 35FL121 Tel+, and pure medium | Medium with cells | [75] |
|
Online (ESI)MS | Breast cancer | T47D, SKBR-3, and MDA-MB-231 | HMLE | Cell-free culture medium | [77] |
|